News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SYGNIS Pharma AG Enters Final Stage with its Phase II Efficacy Study of AX200 for the Treatment of Acute Stroke



3/22/2011 10:38:26 AM

Heidelberg, 22 March 2011 – SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard), a clinical stage biotech company developing innovative CNS treatments, today announced that the independent Data Safety Monitoring Board (DSMB), which is responsible for monitoring safety issues with regard to the execution of the Phase II efficacy study of AX200 for the treatment of acute ischemic Stroke (AXIS 2), has held its final interim review before the end of the trial and recommended its unmodified continuation.

Based on the data of 75% of the 328 AXIS 2-patients the DSMB held its third interim review. As the accessible study-data continues to show the administration of AX200 is safe and well tolerated by the patients, the DSMB confirmed its recommendation of December 2010 when of 50% of all AXIS 2-patients were recruited.

Dr Frank Rathgeb, Chief Medical Officer of SYGNIS, said: "The patient recruitment for AXIS 2 has improved significantly in recent months and the data continues to show AX200 has a good safety profile. Therefore, we should be in a good position to report the top-line data in the second half of 2011."

About SYGNIS Pharma

SYGNIS Pharma AG, headquartered in Heidelberg, is a specialty pharmaceutical company listed on the Prime Standard of the German stock exchange. The Company is focused on the research and development of innovative therapies for the treatment of disorders of the Central Nervous System. SYGNIS’ core projects are currently Acute Stroke for which SYGNIS’ lead clinical programme is AX200 as well as the preclinical KIBRA-project for the treatment of different forms of dementia. All these disorders are characterized by the fact that, as the disease progresses, nerve cells are damaged and die. Although there is great medical demand, there are currently no or only inadequate treatment options available. SYGNIS’ strategy for growth includes the development of new products from its own research and through in-licensing and acquisitions.

For further information please contact:

SYGNIS Pharma AG: Dr. Franz-Werner Haas Senior Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de

Media-Contact:

Julia Phillips Financial Dynamics Tel.: +44 (0) 20 7269 7187


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES